» Articles » PMID: 38709708

Transcriptomic Signatures of Progression to Tuberculosis Disease Among Close Contacts in Brazil

Abstract

Background: Approximately 5% of people infected with Mycobacterium tuberculosis progress to tuberculosis (TB) disease without preventive therapy. There is a need for a prognostic test to identify those at highest risk of incident TB so that therapy can be targeted. We evaluated host blood transcriptomic signatures for progression to TB disease.

Methods: Close contacts (≥4 hours of exposure per week) of adult patients with culture-confirmed pulmonary TB were enrolled in Brazil. Investigation for incident, microbiologically confirmed, or clinically diagnosed pulmonary or extrapulmonary TB disease through 24 months of follow-up was symptom triggered. Twenty previously validated blood TB transcriptomic signatures were measured at baseline by real-time quantitative polymerase chain reaction. Prognostic performance for incident TB was tested by receiver operating characteristic curve analysis at 6, 9, 12, and 24 months of follow-up.

Results: Between June 2015 and June 2019, 1854 close contacts were enrolled. Twenty-five progressed to incident TB, of whom 13 had microbiologically confirmed disease. Baseline transcriptomic signature scores were measured in 1789 close contacts. Prognostic performance for all signatures was best within 6 months of diagnosis. Seven signatures (Gliddon4, Suliman4, Roe3, Roe1, Penn-Nicholson6, Francisco2, and Rajan5) met the minimum World Health Organization target product profile for a prognostic test through 6 months and 3 signatures (Gliddon4, Rajan5, and Duffy9) through 9 months. None met the target product profile threshold through ≥12 months of follow-up.

Conclusions: Blood transcriptomic signatures may be useful for predicting TB risk within 9 months of measurement among TB-exposed contacts to target preventive therapy administration.

Citing Articles

A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.

Lange C, Bothamley G, Gunther G, Guglielmetti L, Kontsevaya I, Kuksa L Pathog Immun. 2025; 10(2):1-45.

PMID: 40062355 PMC: 11888605. DOI: 10.20411/pai.v10i2.791.

References
1.
Mendelsohn S, Mbandi S, Fiore-Gartland A, Penn-Nicholson A, Musvosvi M, Mulenga H . Prospective multicentre head-to-head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real-time PCR. Commun Med (Lond). 2022; 2(1). PMC: 8954216. DOI: 10.1038/s43856-022-00086-8. View

2.
Houben R, Dodd P . The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. PLoS Med. 2016; 13(10):e1002152. PMC: 5079585. DOI: 10.1371/journal.pmed.1002152. View

3.
Roe J, Venturini C, Gupta R, Gurry C, Chain B, Sun Y . Blood Transcriptomic Stratification of Short-term Risk in Contacts of Tuberculosis. Clin Infect Dis. 2019; 70(5):731-737. DOI: 10.1093/cid/ciz252. View

4.
Abubakar I, Drobniewski F, Southern J, Sitch A, Jackson C, Lipman M . Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. Lancet Infect Dis. 2018; 18(10):1077-1087. PMC: 6192014. DOI: 10.1016/S1473-3099(18)30355-4. View

5.
Singhania A, Verma R, Graham C, Lee J, Tran T, Richardson M . A modular transcriptional signature identifies phenotypic heterogeneity of human tuberculosis infection. Nat Commun. 2018; 9(1):2308. PMC: 6008327. DOI: 10.1038/s41467-018-04579-w. View